In a significant move, the Supreme Court of Canada has granted four pharma entities, including Sanis Health, Shoppers Drug Mart, Sandoz Canada, and McKesson Canada, the right to challenge a notable class action proposed by the province of British Columbia, as per a report by JD Supra.
This class action is grounded under British Columbia’s Opioid Damages and Health Care Costs Recovery Act (ORA). The case in question is Sandoz Canada v British Columbia, 2023 BCCA 306, with the four entities acting as defendants.
In general, proposed class actions of this kind, often referred to as “multi-Crown” actions, provide a framework for multiple governmental bodies to enact litigation as a singular entity, aiming to recover healthcare costs related to widespread issues. Given its significance, this case is of note to legal professionals especially those dealing with healthcare, public policy and large corporations.
What’s specific in this case is that the Supreme Court decision could have far-reaching implications for future class actions under the ORA, and by extension, influence legal procedures and frameworks considerably.
The comprehensive details of the class action, its key arguments, parties involved, and potential legal implications are yet to be disclosed. However, keeping a close track of developments is paramount for understanding the potential shifts in the legal landscape.